Symptomatic CRT Patients: Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence

Stopped early

Conditions studied: Heart Failure

In brief

The purpose of this study is to develop valid scientific evidence of the safety and benefit of Barostim Therapy in the commercial setting in patients that are symptomatic despite having received CRT.

Key facts

Study ID

NCT05860348

Run by

CVRx, Inc.

People needed

5

Starts

2023-07-25

Expected to finish

2024-12-11

Last updated by the study team

2025-04-08

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients can be included if they were implanted with a cardiac resynchronization therapy (CRT) device at least six months (180 days) prior to informed consent and are planned for a de novo Barostim System implantation. Patients must sign an informed consent form before implantation with the Barostim System in order to participate in this study.

You may not qualify if…

• Patients cannot be enrolled and active in another (e.g. device, pharmaceutical, or biological) clinical study unless approved by the CVRx Clinical department.

Where it is running

• Aurora Denver Cardiology Associates — Aurora, Colorado, United States
• Florida Heart Rhythm Specialists — Fort Lauderdale, Florida, United States
• Advanced Cardiology — Hackettstown, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.